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D-Dimer Predicts Early Clinical Progression
in Ischemic Stroke
Confirmation Using Routine Clinical Assays
Mark Barber, MD, MRCP; Peter Langhorne, PhD, FRCP; Ann Rumley, PhD;
Gordon D.O. Lowe, MD, FRCP; David J. Stott, MD, FRCP
Background and Purpose—Plasma D-dimer levels, measured using a research laboratory assay, independently predict
progressing ischemic stroke. We wished to confirm these findings using commercially available assays and to provide
data to allow the design of intervention studies.
Methods—We studied 219 consecutive acute ischemic stroke admissions of whom 54 (25%) met criteria for progressing
stroke.
Results—There were strong correlations between D-dimer results as measured by the Biopool AB, MDA and VIDAS
assays; correlation coefficients r0.91 to 0.94; all P0.001. In binary logistic regression analyses, D-dimer, as
measured by the 3 different assays, was an independent predictor of progressing stroke (odds ratios, 1.87 to 2.45; all
P0.001). This confirms the results of our original analysis (Biopool AB) using 2 commercial D-dimer assays,
demonstrating the potential usefulness of D-dimer in providing early prognostic information after ischemic stroke in
different clinical settings. We also provide information on the performance of the 3 assays in predicting progressing
stroke at a variety of cutoff values.
Conclusions—Ischemic stroke patients at high risk of early progression can be identified using commercial D-dimer
measurements. This could allow selection of high-risk patients for inclusion in randomized trials of early antithrombotic
treatments. (Stroke. 2006;37:1113-1115.)
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Early clinical progression of ischemic stroke is commonand is associated with poor prognosis.1 D-dimer levels
are elevated in the acute phase of stroke and subsequently
fall.2–4 We previously demonstrated that plasma D-dimer
levels (along with mean arterial blood pressure) indepen-
dently predict progressing ischemic stroke.5 This measure-
ment of D-dimer was performed with a commercially avail-
able ELISA from Biopool AB used in our research
laboratory. We wished to confirm our findings using other
commercially available assays commonly used by hospital
laboratories, particularly the MDA and VIDAS D-dimer
assays.
Materials and Methods
We studied consecutive ischemic stroke admissions.5 Progressing
stroke was defined using a modification of the European Progressing
Stroke Study definition.6 This requires deterioration in conscious
level, arm or leg weakness, or speech over 72 hours following
admission. Blood was taken within 24 hours of symptom onset, and
plasma samples were stored at 80°C before analysis. The MDA
D-dimer assay is an automated latex particle-based immunoassay,
and the VIDAS D-dimer assay is an automated enzyme-linked
fluorescent assay.7
Univariate analysis of D-dimer levels used unpaired t tests of
natural log-transformed levels. Correlations between the different
assays were calculated using the Spearman rank method. Multivar-
iate analysis was performed using a stepwise binary logistic regres-
sion procedure including variables when significance was found to
be P0.10 in univariate analysis.
Results
Fifty-four (25%) of the 219 patients recruited met the criteria
for progressing stroke. Results were unavailable for 7 of the
MDA D-dimer assays and 5 of the VIDAS D-dimer assays.
There were strong correlations between D-dimer results as
measured by the 3 assays: correlation coefficient r0.94
between the Biopool AB and MDA assays; r0.92 between
the Biopool AB and VIDAS assays; and r0.91 between the
MDA and VIDAS assays (all P0.001). Median D-dimer
levels were higher in the progressing stroke group compared
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with the group with no progression using both the MDA
assay (597 versus 348 ng/mL; P0.00002) and the VIDAS
assay (863 versus 407 ng/mL; P0.00002). The results of the
binary logistic regression analyses for the MDA and VIDAS
D-dimer assays are shown in Table 1. These results were very
similar to those of the original analysis using the Biopool AB
ELISA.5 Table 2 shows the sensitivity, specificity, and
positive predictive values for progressing stroke at percentile
cutoffs using the 3 assays.
Discussion
We confirmed the results of our original analysis using 2
alternative and commonly used routine D-dimer assays. This
confirms the potential usefulness of D-dimer in providing
early prognostic information after ischemic stroke in different
clinical settings. As a test, D-dimer has the advantage over
other measures of thrombin generation (such as prothrombin
fragment 12 and thrombin–antithrombin complex levels) in
that levels are resistant to ex vivo activation and have a long
half-life. The VIDAS assay has already been recently shown
to be of potential clinical value in prediction of a high-risk
group for proximal deep vein thrombosis among patients with
acute stroke.8
We also provide information on the performance of the 3
assays at different cutoff values. It appears that the MDA and
VIDAS D-dimer assays may perform marginally better than
the Biopool assay as predictors of progressing ischemic
stroke. This may reflect the fact that the Biopool assay we
used has been set up to have greater analytical sensitivity at
lower levels (important for epidemiological studies).
Strengths and weaknesses of this study are those of the
original project.5 We studied a large consecutive group of
subjects using few exclusion criteria. A single researcher
assessed all patients. However, samples were taken within 24
hours of symptom recognition, rather than immediately, and
detailed functional imaging was not performed as part of the
study protocol.
Previous studies specifically designed to assess prevention
of progressing stroke using anticoagulant or antiplatelet
therapy have been negative9–11 (perhaps, in part, because a
high-risk subgroup was not identified for recruitment). If, as
we suggested previously, D-dimer is used to help target
interventions aimed at preventing early neurological deterio-
ration after acute ischemic stroke, then appropriate cutoff
levels can be chosen for these different assays depending on
the potential risks and benefits of the intervention used.5 For
example, levels above the median (401 ng/mL for MDA; 513
ng/mL for VIDAS) identify 50% of patients in whom the risk
of early progression is 33% compared with a risk of 16% in
patients with below-median levels. Higher-risk groups for
early (ischemic) progression, identified in this way, may
merit consideration for randomized trials of early antithrom-
botic treatments (for example, heparins or new antiplatelet
agents). Such trials of selective antithrombotic treatment
should record neuroimaging data, stroke etiology, and the
causes of progressing stroke. In addition, blood samples
should be withdrawn earlier. These studies should ideally
include, as end points, not only progressing stroke along
with the modified Rankin scale and Barthel Index (the
latter 2 at 3 months), but also venous thromboembolism.8
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TABLE 2. Sensitivity, Specificity, and Positive Predictive Values for Progressing Stroke at Percentile
Cutoffs Using the 3 D-Dimer Assays
D-Dimer Assay Percentile Value, ng/mL Sensitivity Specificity Positive Predictive Value
Biopool AB 90th 1362 9/54 (17%) 151/164 (92%) 9/22 (41%)
75th 586 21/54 (39%) 131/164 (80%) 21/54 (39%)
50th 229 37/54 (69%) 92/164 (56%) 37/109 (34%)
25th 105 49/54 (91%) 49/164 (30%) 49/164 (30%)
MDA 90th 1294 11/52 (21%) 150/160 (94%) 11/21 (52%)
75th 672 23/52 (44%) 130/160 (81%) 23/53 (43%)
50th 401 35/52 (67%) 89/160 (56%) 35/106 (33%)
25th 211 47/52 (90%) 48/160 (30%) 47/159 (30%)
VIDAS 90th 1749 11/53 (21%) 151/161 (94%) 11/21 (52%)
75th 964 23/53 (43%) 131/161 (81%) 23/53 (43%)
50th 513 35/53 (66%) 89/161 (55%) 35/107 (33%)
25th 277 47/53 (89%) 47/161 (29%) 47/161 (29%)
TABLE 1. Logistic Regression Model of Independent Predictors
of Progressing Ischemic Stroke, Including D-Dimer, by the MDA
assay (a) and the VIDAS assay (b)
B (SE) r
Odds
Ratio
P
Value
a) Constant 8.989 (1.884)
MABP (per
10 mm Hg)
0.238 (0.093) 0.146 1.27 0.01
Natural log D-dimer 0.856 (0.217) 0.252 2.35 0.0001
b) Constant 9.846 (2.028)
MABP (per
10 mm Hg)
0.219 (0.092) 0.130 1.24 0.02
Natural log D-dimer 0.894 (0.217) 0.263 2.45 0.0001
MABP indicates mean arterial blood pressure.
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